Search Results 1061-1070 of 17070 for monoclonal antibody

1. A Study Evaluating the Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Mayo Clinic

   Anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative; and; An anthracycline containing chemotherapy regimen. Intent to ...

2. A Study to Assess the Effectiveness and Safety of Ublituximab in combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) - Mayo Clinic

   ... antibody (HCV ... History of anaphylaxis (excluding infusion related reactions) in association with previous anti-CD20 monoclonal antibody administration.

3. A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA) - Mayo Clinic

   Positive for human immunodeficiency virus (HIV) or hepatitis C antibody. Positive for hepatitis B surface antigen. Splenectomy within 3 months of screening ...

4. Who should get COVID-19 testing? - Mayo Clinic News Network

   Terms like viral, molecular, serology and antibodies, and convalescent plasma have sprung up in everyday language when talking about COVID-19 — but do you ...

5. A Study of PF-08052666/​SGN-MesoC2 in Advanced Solid Tumors - Mayo Clinic

   SGN-MesoC2 is a type of antibody-drug conjugate (ADC). ADCs are designed to stick to cancer cells and kill them. They may also stick to some normal cells ...

6. Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors - Mayo Clinic

   ... monoclonal antibody (mAb) therapy within 45 days prior to study Day 1. Note: Patients are allowed to receive any of the following treatments up to 7 days ...

7. Ulcerative colitis - Symptoms and causes - Mayo Clinic

   Kaplan GG. Monoclonal antibody risankizumab for ulcerative colitis. JAMA. 2024; doi:10.1001/jama.2024.8819. Related.

8. MC230813 A Study of Golcadomide with Rituximab prior to CAR-T with Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NHL) - Mayo Clinic

   Exception: Monoclonal and bispecific antibodies is acceptable. Prior therapy with golcadomide ≤4 weeks prior to Registration. Prior autologous SCT ≤3 ...

9. A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma - Mayo Clinic

   Known hypersensitivity to another monoclonal antibody that cannot be controlled with standard measures (e.g., antihistamines and corticosteroids). Inability ...

10. Axicabtagene Ciloleucel Expanded Access Study - Mayo Clinic

    anti-CD20 monoclonal antibody unless investigator determines that tumor is CD20 negative; and; an anthracycline containing chemotherapy regimen. No evidence ...